Virax Biolabs Group Shares Set to Reverse Split on Monday, June 29th (NASDAQ:VRAX)

Virax Biolabs Group Limited (NASDAQ:VRAX)’s stock is going to reverse split on Monday, June 29th. The 1-25 reverse split was announced on Wednesday, June 24th. The number of shares owned by shareholders will be adjusted after the market closes on Friday, June 26th.

Virax Biolabs Group Stock Performance

VRAX opened at $0.13 on Thursday. The business has a fifty day moving average of $0.18 and a 200 day moving average of $0.24. Virax Biolabs Group has a 52-week low of $0.10 and a 52-week high of $1.14.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Wednesday, April 8th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Virax Biolabs Group presently has an average rating of “Hold” and a consensus target price of $1.00.

About Virax Biolabs Group

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.